

Inhibition of DNA recombination at te-

lomere



Hayashi, MT., Orlic-Milacic, M.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of Creative Commons Attribution 4.0 International (CC BY 4.0) License. For more information see our license.

15/09/2021

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics, 18,* 142. 7
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467.
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res, 46*, D649-D655.
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, *14*, e1005968. *¬*

Reactome database release: 77

This document contains 1 pathway and 4 reactions (see Table of Contents)

Inhibition of DNA recombination at telomere 7

Stable identifier: R-HSA-9670095

Compartments: nucleoplasm



Telomeres resemble double strand DNA breaks (DSBs) and, if not properly packaged and protected, are recognized by the DNA double strand break repair (DSBR) machinery. Initiation of DSB signaling at telomeres due to replicative shortening of telomeres is one of the triggers of cellular senescence, which can also be triggered by other cellular stressors, such as oxidative stress, and oncogenic signaling-induced mitotic arrest. The loss of telomere protection can result in telomere fusions via non-homologous end joining (NHEJ) of microhomology-mediated end joining (MMEJ). Loss of telomere protection accompanied by changes in the organization of telomeric chromatin (O'Sullivan et al. 2014) can trigger extension of telomeres via homologous recombination repair-mediated alternative lengthening of telomeres (ALT). ALT occurs in about 5-15% of cancers and is a telomerase-independent mechanism of replicative immortality. For review, please refer to Arnoult and Karlseder 2015 and Pickett and Reddel 2015.

Literature references

- Arnoult, N., Karlseder, J. (2015). Complex interactions between the DNA-damage response and mammalian telomeres. *Nat. Struct. Mol. Biol., 22*, 859-66. 7
- Pickett, HA., Reddel, RR. (2015). Molecular mechanisms of activity and derepression of alternative lengthening of telomeres. *Nat. Struct. Mol. Biol., 22*, 875-80. 🛪
- O'Sullivan, RJ., Kubicek, S., Schreiber, SL., Karlseder, J. (2010). Reduced histone biosynthesis and chromatin changes arising from a damage signal at telomeres. *Nat. Struct. Mol. Biol.*, *17*, 1218-25.

2019-12-19	Authored	Orlic-Milacic, M.
2020-04-29	Reviewed	Hayashi, MT.
2020-05-04	Edited	Orlic-Milacic, M.

ATRX binds DAXX 7

Location: Inhibition of DNA recombination at telomere

Stable identifier: R-HSA-9007926

Type: binding

Compartments: nucleoplasm



ATRX (Alpha-thalassemia mental retardation syndrome X-linked) binds to transcriptional co-activator DAXX (Death domain-associated protein 6) to form an ATP-dependent chromatin remodeling complex with triple-helix displacement activity (Xue et al. 2003).

Literature references

Xue, Y., Gibbons, R., Yan, Z., Yang, D., McDowell, TL., Sechi, S. et al. (2003). The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies. *Proc. Natl. Acad. Sci. U.S.A.*, 100, 10635-40. *¬*

2019-12-19	Authored	Orlic-Milacic, M.
2020-04-29	Reviewed	Hayashi, MT.
2020-05-04	Edited	Orlic-Milacic, M.

ATRX:DAXX binds to subtelomeric chromosomal regions 7

Location: Inhibition of DNA recombination at telomere

Stable identifier: R-HSA-9670101

Type: binding

Compartments: nucleoplasm



The complex of ATRX (Alpha-thalassemia mental retardation syndrome X-linked) and DAXX (Death domain-associated protein 6) binds to subtelomeric chromosomal regions and plays a role in the recruitment of cohesin to subtelomeric regions and in the regulation of transcription of the noncoding telomeric repeat-containing RNA (TERRA) (Eid et al. 2015).

Followed by: Histone H3.3 deposition at telomere

Literature references

Eid, R., Demattei, MV., Episkopou, H., Augé-Gouillou, C., Decottignies, A., Grandin, N. et al. (2015). Genetic Inactivation of ATRX Leads to a Decrease in the Amount of Telomeric Cohesin and Level of Telomere Transcription in Human Glioma Cells. *Mol. Cell. Biol.*, 35, 2818-30. ↗

2019-12-19	Authored	Orlic-Milacic, M.
2020-04-29	Reviewed	Hayashi, MT.
2020-05-04	Edited	Orlic-Milacic, M.

Histone H3.3 deposition at telomere *▼*

Location: Inhibition of DNA recombination at telomere

Stable identifier: R-HSA-9670114

Type: transition

Compartments: nucleoplasm



ATRX (Alpha-thalassemia mental retardation syndrome X-linked) and its binding partner DAXX (Death domain-associated protein 6) are required for deposition of histone H3.3, encoded by either the H3F3A gene or the H3F3B gene, to telomeres, independently of the H3.3 chaperone HIRA, in both human and mouse embryonic stem cells. Highly evolutionarily conserved N-terminus of DAXX interacts directly with the H3.3 core (Goldberg et al. 2010, Lewis et al. 2010).

Preceded by: ATRX: DAXX binds to subtelomeric chromosomal regions

Literature references

- Goldberg, AD., Banaszynski, LA., Noh, KM., Lewis, PW., Elsaesser, SJ., Stadler, S. et al. (2010). Distinct factors control histone variant H3.3 localization at specific genomic regions. *Cell*, 140, 678-91.
- Lewis, PW., Elsaesser, SJ., Noh, KM., Stadler, SC., Allis, CD. (2010). Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. *Proc. Natl. Acad. Sci. U.S.A.,* 107, 14075-80. 7

2019-12-19	Authored	Orlic-Milacic, M.
2020-04-29	Reviewed	Hayashi, MT.
2020-05-04	Edited	Orlic-Milacic, M.

TERRA transcription ↗

Location: Inhibition of DNA recombination at telomere

Stable identifier: R-HSA-9670149

Type: omitted

Compartments: nucleoplasm



Transcription of the telomeric noncoding RNA TERRA (the telomere repeat-containing RNA) is inhibited by ATRX (Flynn et al. 2015). Tumors with ATRX and DAXX mutations associated with the alternative lengthening of telomeres (ALT) show increased TERRA levels (Barthel et al. 2017).

Literature references

Flynn, RL., Cox, KE., Jeitany, M., Wakimoto, H., Bryll, AR., Ganem, NJ. et al. (2015). Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. *Science*, 347, 273-7.

2019-12-19	Authored	Orlic-Milacic, M.
2020-04-29	Reviewed	Hayashi, MT.
2020-05-04	Edited	Orlic-Milacic, M.

Table of Contents

Introduction	1
Finitiation of DNA recombination at telomere	2
➤ ATRX binds DAXX	3
➢ ATRX:DAXX binds to subtelomeric chromosomal regions	4
➢ Histone H3.3 deposition at telomere	5
TERRA transcription	6
Table of Contents	7